MTFB - Motif Bio plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.30
+0.20 (+2.47%)
At close: 3:35PM EDT
Stock chart is not supported by your current browser
Previous Close8.10
Open8.10
Bid5.00 x 900
Ask9.46 x 900
Day's Range8.30 - 8.49
52 Week Range7.90 - 11.52
Volume3,705
Avg. Volume1,534
Market Cap119.76M
Beta (3Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.33
Trade prices are not sourced from all markets
  • Zacks Small Cap Research18 days ago

    MTFB: Additional Data for Iclaprim Presented at ESCMID/ASM…

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. In addition, the U.S. Food and Drug Administration (FDA) has granted iclaprim orphan drug designation (ODD) for the treatment of bacterial infections in patients with cystic fibrosis caused by Staphylococcus aureus.

  • GlobeNewswire18 days ago

    Motif Bio Presents New Iclaprim Data at IDWeek

    Iclaprim safety and efficacy in patients with wound infections in REVIVE Phase 3 trials NEW YORK, Oct. 03, 2018 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage.

  • GlobeNewswire26 days ago

    Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress

    NEW YORK, Sept. 25, 2018 -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD.

  • GlobeNewswirelast month

    Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences

    Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at two upcoming scientific conferences. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialise its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled “Risk Factors” in Motif Bio’s Annual Report on Form 20-F filed with the SEC on April 10, 2018, which is available on the SEC’s web site, www.sec.gov.

  • GlobeNewswirelast month

    Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region

    Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Director, Mid Atlantic Region. An experienced life science executive and former investment banker, Mr. Dickey will direct the firm’s strategy and service to clients in the region’s fast-growing life science clusters. “Danforth has assembled a first-rate team with deep expertise in accounting, finance strategy and operations for life science companies, allowing both start-ups and growth-stage clients to benefit from the highest level of talent in a flexible and capital-efficient way,” said Mr. Dickey.

  • GlobeNewswire2 months ago

    Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference

    Iclaprim overview presented in State of the Art Lecture Safety analysis of diabetic patients in REVIVE ABSSSI trials shows fewer adverse events versus vancomycin Surveillance data confirm in vitro activity ...

  • Zacks Small Cap Research2 months ago

    MTFB: NDA for Iclaprim Accepted by FDA; PDUFA Date of Feb. 13, 2019…

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. In addition, the U.S. Food and Drug Administration (FDA) has granted iclaprim orphan drug designation (ODD) for the treatment of bacterial infections in patients with cystic fibrosis caused by Staphylococcus aureus.

  • GlobeNewswire2 months ago

    Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference

    NEW YORK, Aug. 17, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European ...

  • GlobeNewswire2 months ago

    Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections

    Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for iclaprim, a targeted, Gram-positive investigational antibiotic, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). This means that the FDA has determined that the application is sufficiently complete to perform a substantive review. The NDA has been granted Priority Review, and the FDA has set a target decision date under the Prescription Drug User Fee Act (PDUFA) of February 13, 2019.

  • GlobeNewswire2 months ago

    Motif Bio to Present at Investor Events in August and September

    NEW YORK, Aug. 09, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will participate at the following investor ...

  • GlobeNewswire2 months ago

    Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037

    NEW YORK, Aug. 08, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received a Notice of Allowance from ...

  • Zacks Small Cap Research4 months ago

    MTFB: Completes Submission of NDA for Iclaprim

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. In addition, the U.S. Food and Drug Administration (FDA) has granted iclaprim orphan drug designation (ODD) for the treatment of bacterial infections in patients with cystic fibrosis caused by Staphylococcus aureus.

  • PR Newswire5 months ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • Zacks Small Cap Research6 months ago

    MTFB: Initiates NDA Submission for Iclaprim

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. In addition, the U.S. Food and Drug Administration (FDA) has granted iclaprim orphan drug designation (ODD) for the treatment of bacterial infections in patients with cystic fibrosis caused by Staphylococcus aureus.

  • PR Newswire6 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...